Modified Laminin E8 for Feeder-Free Stem Cell Culture

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for maintaining human stem cells in regenerative medicine require feeder cells and xenogeneic components, limiting their clinical application due to safety and availability concerns, and existing extracellular matrices like Matrigel are not suitable for human stem cell culture as they are mouse-derived and lack a uniform chemical composition.

Innovation Solution

A modified human laminin is developed by fusing cell adhesion domains or growth factor binding domains with a laminin E8 fragment, creating a culture substrate that supports pluripotency and adhesion of stem cells in a feeder-free and xeno-free environment, using recombinant techniques to produce the modified laminin as an extracellular matrix.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If feeder cells and xenogeneic components are used to maintain human stem cells, then stem cell pluripotency and adhesion are supported, but safety and clinical applicability are compromised

Engineering Contradiction:
ImprovesafetyVSAvoidstem cell maintenance capability
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention segments the complex extracellular matrix into specific functional domains (laminin E8 fragment with cell adhesion domains or growth factor binding domains) that can be produced recombinantly in human cell lines, eliminating the need for xenogeneic components while maintaining stem cell support functions

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention creates a human-derived copy of the essential extracellular matrix components (laminin E8 fragment) that mimics the function of xenogeneic matrices like Matrigel, allowing stem cell culture without mouse-derived products

Inventive Principle:
Principle #26Copying

2Adaptability or versatility

If Matrigel is used as an extracellular matrix, then stem cell adhesion and pluripotency maintenance are effective, but the matrix is not suitable for human stem cell culture due to mouse origin and unknown composition

Engineering Contradiction:
Improvestem cell adhesion efficiencyVSAvoidcomposition uniformity
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The invention changes the source and composition parameters of the extracellular matrix from xenogeneic crude extracts (Matrigel) to recombinant human proteins with defined sequences and structures, achieving both human compatibility and composition uniformity

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite functional structure by fusing cell adhesion domains (such as cell binding domains from fibronectin or vitronectin) or growth factor binding domains with the laminin E8 fragment, combining multiple functional elements into a single recombinant protein

Inventive Principle:
Principle #40Composite materials

3Reliability

If human vitronectin or human fibronectin are used as extracellular matrices, then xeno-free culture is achieved, but adhesion efficiency and pluripotency maintenance are inferior to Matrigel

Engineering Contradiction:
Improvexeno-free statusVSAvoidadhesion efficiency
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention merges the advantages of different extracellular matrix components by fusing cell adhesion domains or growth factor binding domains with laminin E8 fragment, creating a hybrid protein that combines adhesion, signaling, and structural functions in a single human-derived molecule

Inventive Principle:
Principle #5Merging (Combining)

Data Source

PatentEP2695894B1Modified laminin and use thereof
Publication Date: 2017.11.01 OSAKA UNIVERSITY
  • EP2695894B1 patent drawingFigure 1~2
  • EP2695894B1 patent drawingFigure 3
  • EP2695894B1 patent drawingFigure 4

AI summary

Provided are a modified laminin having a cell-growth regulatory molecule bound to at least one site selected from the α chain N-terminus, the α chain C-terminus, the β chain N-terminus and the γ chain N-terminus of laminin or a heterotrimeric laminin fragment, a method for culturing cells in the presence of the modified laminin, a method for establishing iPS cells in the presence of the modified laminin, and a culture substrate coated with the modified laminin. Human stem cells cultured in a xeno-free environment with the use of the modified laminin of the present invention can be provided as highly safe human stem cells applicable to regenerative medicine.